tradingkey.logo

European Commission Approves Johnson & Johnson’S Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen

ReutersApr 7, 2025 1:10 PM

- Johnson & Johnson JNJ.N:

  • EUROPEAN COMMISSION APPROVES JOHNSON & JOHNSON’S SUBCUTANEOUS DARZALEX® (DARATUMUMAB)-BASED QUADRUPLET REGIMEN FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, REGARDLESS OF TRANSPLANT ELIGIBILITY

Source text: [ID:]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI